Although a totally different mechanism for heart failure it had a long trial life with Amgen. Omecamtiv mecarbil, now in phase 2, may now get more attention from Amgen.
Good Info. Hopefully, New York time or SeekingAlph to mention CYTK again.
Wow, CYTK move to Front line on two drugs within two weeks. It created a space for mgmnt to drive. It is showtime.